FDA supplemental approval: Acyclovir (Labeling)

AI Summary

This is an FDA supplemental approval action authorizing labeling changes to acyclovir 400 mg and 800 mg oral tablets by sponsor Yiling, effective 24 June 2026. The record documents a regulatory submission and approval but contains no clinical trial data, efficacy outcomes, safety analyses, or comparative evidence.

Plain-language summary

FDA supplemental approval for acyclovir labeling update; clarifies product information but does not constitute clinical evidence of efficacy or safety.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This regulatory record does not communicate clinical efficacy, safety, or comparative benefit. Clinicians should refer to the updated product labeling and established acyclovir safety and efficacy literature for clinical guidance.

Caveats

• Record does not contain clinical trial results, efficacy data, or safety analyses.
• Specific labeling changes are not detailed in this FDA record.
• No information on indication, dosing rationale, or comparators is provided.
• This is a supplemental approval; prior approval history is not included.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.